Body Mass Index Is Associated with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

ABSTRACT

BACKGROUND: Prior work suggested that patients with inflammatory bowel diseases (IBD) have lower body mass index (BMI) than controls and patients with lower BMI have more serious complications. GOAL The study was aimed to find relationship between BMI in patients with and without IBD, investigate effects of medicine therapy and disease stages on patients' BMI. METHODS: Potentially eligible studies were identified through searching PubMed, Cochrane and Embase databases. Outcome measurements of mean BMI and the number of patients from each study were pooled by a random-effect model. Publication bias test, sensitivity analysis and subgroup analysis were conducted. RESULTS: A total of 24 studies containing 1442 patients and 2059 controls were included. Main results were as follows (1) BMI in Crohn's disease (CD) patients was lower than that in health controls (-1.88, 95% CI -2.77 to -1.00, P< 0.001); (2) Medical therapy significantly improved BMI of CD patients (with therapy -1.58, -3.33 to 0.16; without -2.09, 95% CI -3.21 to -0.98) while on the contrary not significantly improving BMI of UC patients (with therapy -0.24, 95% CI -3.68 to 3.20; without -1.34, 95% CI -2.87 to 0.20, P = 0.57); (3) Both CD and UC patients in active phase showed significantly greater BMI difference compared with controls than those in remission (CD patients remission -2.25, 95% CI -3.38 to -1.11; active phase -4.25, 95% CI -5.58 to -2.92, P = 0.03; UC patients remission 0.4, 95% CI -2.05 to 2.84; active phase -5.38, -6.78 to -3.97, P = 0.001). CONCLUSIONS: BMI is lower in CD patients; medical therapy couldn't improve BMI of IBD patients; the state of disease affects BMI of CD patients and UC patients.